{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=42",
    "query": {
      "intervention": "Protein Control",
      "page": 42
    },
    "page_size": 10
  },
  "pagination": {
    "page": 42,
    "page_size": 10,
    "total_count": 3499,
    "total_pages": 350,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=43&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=41&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T22:01:25.772Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00304083",
      "title": "Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurofibromatosis Type 1",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Sarcoma Alliance for Research through Collaboration",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 48,
      "start_date": "2005-12",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2018-09-18",
      "last_synced_at": "2026-10-29T22:01:25.772Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Santa Monica, California • Chicago, Illinois + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00304083"
    },
    {
      "nct_id": "NCT00097786",
      "title": "Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Valsartan 160 mg + nateglinide 60 mg",
          "type": "DRUG"
        },
        {
          "name": "Valsartan 160 mg + nateglinide placebo",
          "type": "DRUG"
        },
        {
          "name": "Nateglinide 60 mg + valsartan placebo",
          "type": "DRUG"
        },
        {
          "name": "Valsartan placebo + nateglinide placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "50 Years to 99 Years"
      },
      "enrollment_count": 9306,
      "start_date": "2002-01",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2023-11-08",
      "last_synced_at": "2026-10-29T22:01:25.772Z",
      "location_count": 1,
      "location_summary": "Multiple Locations, New Jersey",
      "locations": [
        {
          "city": "Multiple Locations",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00097786"
    },
    {
      "nct_id": "NCT00900302",
      "title": "OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "protein expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "Up to 120 Years"
      },
      "enrollment_count": 98,
      "start_date": "2005-04",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2016-02-10",
      "last_synced_at": "2026-10-29T22:01:25.772Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00900302"
    },
    {
      "nct_id": "NCT00485134",
      "title": "Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Shigellosis"
      ],
      "interventions": [
        {
          "name": "240 µg Shigella flexneri 2a Invaplex 50 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "480 µg Shigella flexneri 2a Invaplex 50 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "690 Shigella flexneri 2a Invaplex 50 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Shigella challenge strain",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 113,
      "start_date": "2007-05",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2017-09-11",
      "last_synced_at": "2026-10-29T22:01:25.772Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Silver Spring, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00485134"
    },
    {
      "nct_id": "NCT00842309",
      "title": "D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Body Dysmorphic Disorder"
      ],
      "interventions": [
        {
          "name": "d-cycloserine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2008-11",
      "completion_date": "2018-08",
      "has_results": true,
      "last_update_posted_date": "2019-06-18",
      "last_synced_at": "2026-10-29T22:01:25.772Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00842309"
    },
    {
      "nct_id": "NCT02438787",
      "title": "A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Axial Spondyloarthritis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 45 mg",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab 90 mg",
          "type": "DRUG"
        },
        {
          "name": "Golimumab 50 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 315,
      "start_date": "2015-07-31",
      "completion_date": "2017-08-31",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-10-29T22:01:25.772Z",
      "location_count": 19,
      "location_summary": "Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 16 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02438787"
    },
    {
      "nct_id": "NCT03737643",
      "title": "Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Placebo olaparib",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab placebo",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin+Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 130 Years · Female only"
      },
      "enrollment_count": 1407,
      "start_date": "2019-01-04",
      "completion_date": "2026-12-23",
      "has_results": true,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-10-29T22:01:25.772Z",
      "location_count": 26,
      "location_summary": "Foothill Ranch, California • Los Angeles, California • Orange, California + 22 more",
      "locations": [
        {
          "city": "Foothill Ranch",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03737643"
    },
    {
      "nct_id": "NCT00125268",
      "title": "Near Infrared Light for the Treatment of Painful Peripheral Neuropathy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Peripheral Neuropathy"
      ],
      "interventions": [
        {
          "name": "MIRE",
          "type": "DEVICE"
        },
        {
          "name": "Sham Device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 30,
      "start_date": "2005-07",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2012-09-05",
      "last_synced_at": "2026-10-29T22:01:25.772Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00125268"
    },
    {
      "nct_id": "NCT03400852",
      "title": "A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Muscular Dystrophy, Duchenne"
      ],
      "interventions": [
        {
          "name": "MNK-1411",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mallinckrodt ARD LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "8 Years",
        "sex": "MALE",
        "summary": "4 Years to 8 Years · Male only"
      },
      "enrollment_count": 44,
      "start_date": "2018-07-27",
      "completion_date": "2020-02-25",
      "has_results": true,
      "last_update_posted_date": "2021-03-16",
      "last_synced_at": "2026-10-29T22:01:25.772Z",
      "location_count": 5,
      "location_summary": "Gulf Breeze, Florida • Atlanta, Georgia • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03400852"
    },
    {
      "nct_id": "NCT00221338",
      "title": "Clinical Trial of Gabapentin to Decrease Postoperative Delirium and Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Postoperative Delirium",
        "Postoperative Pain",
        "Opioid Use",
        "Hospital Length of Stay"
      ],
      "interventions": [
        {
          "name": "Gabapentin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 750,
      "start_date": "2006-01",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2020-09-10",
      "last_synced_at": "2026-10-29T22:01:25.772Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00221338"
    }
  ]
}